Monopar TherapeuticsMNPR
About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Employees: 16
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
53,861% more capital invested
Capital invested by funds: $106K [Q3] → $57.1M (+$57M) [Q4]
200% more funds holding
Funds holding: 6 [Q3] → 18 (+12) [Q4]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
41.96% more ownership
Funds ownership: 0.45% [Q3] → 42.41% (+41.96%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Sean Lee 48% 1-year accuracy 14 / 29 met price target | 7%downside $40 | Buy Reiterated | 1 Apr 2025 |
Piper Sandler Biren Amin 23% 1-year accuracy 6 / 26 met price target | 76%upside $76 | Overweight Assumed | 19 Mar 2025 |
Financial journalist opinion









